Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Идёт Фаза II Россия Набор открыт

4-MUST; Placebo

A Prospective Multicenter Randomized Double-blind Placebo-controlled Study in Parallel Groups to Evaluate the Efficacy, Safety, and Tolerability of the Drug 4-MUST, Tablets, 128 mg Administered at Various Doses in Patients With Chronic Cholecystitis and Biliary Dyskinesia

Номер протоколаGIB-02-03-2024
ФазаФаза II
Участников по плану — во всех странах исследования300
Сроки17.10.2024 — 31.12.2026
Начало: 17 октября 2024Окончание: 31 декабря 2026
Пройдено 95% планового срока

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT06842966/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование идёт, в реестре указано, что набор участников открыт.
  • Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 300 чел. во всех странах исследования.
  • Центров в реестре: 17 в 10 городах. Список — ниже на странице.
  • Плановое окончание — 12.2026.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–70 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 41 · невключение: 11

Критерии включения

  • Males and females aged 18-70 years.
  • Presence of established gastrointestinal diseases: Chronic cholecystitis (K81.1); Dyskinesia of the bile duct or gallbladder (K82.8).
  • Presence of pain/discomfort in the upper abdomen combined with at least one of the following symptoms: Heartburn; Belching; Nausea; Abdominal bloating; Borborygmi (stomach rumbling); Flatulence; Constipation; Diarrhea.
  • Maximum severity of pain/discomfort in the upper abdomen over the past week is 40 mm or more on the VAS (Visual Analog Scale).
  • Severity of gastrointestinal symptoms according to the GSRS (Gastrointestinal Symptom Rating Scale) questionnaire is at least 30 points.
  • Women who are either sexually abstinent or using effective contraception methods (e.g. intrauterine devices, contraceptive patches, long-acting injectable contraceptives, or double barrier methods) for at least 8 weeks before and 3 weeks after the end of the study, with a confirmed negative pregnancy test, as well as women with documented infertility or non-childbearing status (e.g. hysterectomy, tubal ligation, infertility or menopause for more than 1 year) or men using barrier contraceptives throughout the study and for 3 weeks after its completion, or men unable to conceive (documented conditions: vasectomy, infertility).
  • Signed and dated informed consent from.
  • Non-inclusion Criteria:
  • Peptic ulcer disease, duodenal ulcer, erosive GERD.
  • Toxic megacolon.
  • Paralytic ileus.
  • Gilbert's syndrome.
  • Abdominal adhesion disease.
  • Blood in stool, unexplained weight loss, fever, anemia.
  • Inflammatory and erosive gastrointestinal diseases.
  • Irritable bowel syndrome, non-specific ulcerative colitis, Crohn's disease.
  • Oncological diseases of the gastrointestinal tract (including past diagnoses).
  • History of gastrointestinal surgical procedures, including but not limited to endoscopic papillotomy and cholecystectomy, exept for appendectomy.
  • Use of prohibited therapy medications within 3 days prior to randomization.
  • History of mental illnesses.
  • Chronic heart failure IIb-III stages and/or III-IV functional classes according to NYHA, angina pectoris III-IV functional classes.
  • Chronic kidney disease stage IIIa-V (according to NKF/KDOQI, 2006).
  • Established diagnosis of liver failure, including in history and/or changes in liver enzyme activity: Increase in AST, ALT, ALP and/or γ-GTP more than 3 times above the upper limit of normal; Increase in total bilirubin more than 2 times above the upper limit of normal or development of jaundice.
  • HIV, syphilis, viral hepatitis B or C, including in history.
  • Lactose intolerance, lactase deficiency, and glucose-galactose malabsorption syndrome.
  • Liver cirrhosis.
  • Hypersensitivity to the active ingridient or any of the excipients of the drug 4-MUST.
  • Severe, decompensated or unstable somatic diseases (any diseases or conditions that threaten the patient's life or worsen their prognosis and make it impossible for the patient to participate in clinical research).
  • Diabetes mellitus in a state of subcompensation and decompensation.
  • Systemic connective tissue diseases.
  • Autoimmune diseases.
  • Need for surgical and/or endovascular treatment and/or necessity for hemodialysis procedures.
  • Epilepsy or seizures of unclear etiology, including in history.
  • Alcoholism, substance abuse or drug addiction, including in history.
  • Uncorrected electrolyte disturbances.
  • History of surgery within 6 month prior to screening.
  • Women during pregnancy or lactation; women planning to become pregnant within the next 6 months.
  • Patients who require prohibited concomitant therapy within this study framework.
  • Participation in another clinical trial within the last 3 months prior to the screening visit date.
  • Lack of willingness to cooperate from the patient's side.
  • Other conditions that, in the investigator's judgement, may preclude the patient's participation in the study.

Критерии невключения

  • Incorrect enrollment of a patient in the study (failure to meet inclusion/exclusion criteria at the time of randomization).
  • Ineffectiveness of therapy. The therapy will be deemed ineffective if there is no clinical improvement by visit 3 (15±1 days of therapy) - persistence or increase in the severity of pain/discomfort in the upper abdomen on the VAS compared to baseline. If excluded, the patient will be assigned alternative treatment at the discretion of the investigator.
  • Patient non-compliance (a compliant patient is defined as one who has taken at least 202 and no more than 303 tablets).
  • Requirement for prohibited concomitant therapy.
  • If the investigator judges that comtinued participation in the study would harm the patient.
  • Pregnancy or the need for breastfeeding in the patient.
  • Gross violation by the patient of the study protocol procedures outlined in the patient information sheet (PIS).
  • Withdrawal of informed consent (patient's unwillingness to continue participation in the study).
  • Loss of contact with the patient (inability to reach the patient via mobile and home phone (if applicable), as well as through a contact person; there must be at least three documented attempts to contact the patient).
  • Emergence during the study of any diseases or conditions that worsen the patient's prognosis, making it impossible for the patient to continue participating in this clinical trial.
  • Any other reasons, including administrative issues, that in the investigator's judgement may interfere with subject's ability to comlete the study.

Источник: ClinicalTrials.gov, NCT06842966 · запись обновлена в реестре 11 июля 2025.

Дизайн и результаты

ДизайнРандомизированное, двойное слепое, параллельные группы; цель — лечение
Участников по плану (все страны)300
Результатыбудут после окончания
Что измеряют — первичные конечные точки (1), вторичных — 56
  • Average reduction in the severity of pain/discomfort in the upper abdomen on the VAS by day 29 compared to baseline — Day 29 ± 1

Цель исследования

This study aims to evaluate the efficacy, safety, and tolerability of the drug 4-MUST at various doses compared to placebo in patients with chronic cholecystitis and biliary dyskinesia

Где проходит

17 центров в 10 городах
Великий Новгород

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06842966 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, набор участников, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.